Piper starts Catalyst Biosciences at Overweight

 With an Overweight rating, Piper Sandler initiated coverage on Catalyst Biosciences Inc (NASDAQ:CBIO). The price target seems to have been set at $15.00 for Catalyst Biosciences. For the third quarter, Catalyst Biosciences had an EPS of $0.73, compared to year-ago quarter EPS of $1.06. 

https://www.benzinga.com/analyst-ratings/upgrades/21/02/19588150/benzingas-top-ratings-upgrades-downgrades-for-february-10-2021